Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

NCT05338190 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG: Combination of Rituximab with subcutaneous belimumab
DRUG: Combination of Rituximab with subcutaneous placebo

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]